Asceniv™

Understanding Asceniv™
Asceniv™ (immune globulin intravenous, human — 10% liquid) is a ready‑to‑use intravenous immune globulin (IVIG) manufactured from pooled human plasma and marketed by ADMA Biologics. It is supplied as a 10% IgG solution for IV infusion intended to provide passive immunoglobulin replacement for patients with antibody‑deficiency disorders.

How Asceniv™ Works:

• Passive antibody replacement: Asceniv™ supplies pooled human IgG antibodies to replace deficient or dysfunctional endogenous immunoglobulins in patients with PIDD, thereby helping restore humoral immune protection.
• Immune support actions: The infused IgG neutralizes pathogens, promotes opsonization, and enhances clearance of bacteria and viruses, reducing the frequency and severity of infections in immunodeficient patients.
• Product‑specific antibody profile: The manufacturer reports Asceniv™’s plasma‑blending process yields elevated titers against certain respiratory viruses compared with standard source plasma; this is a formulation attribute reported by ADMA and not an independent regulatory efficacy claim.
• Administration context: Asceniv™ is given as a weight‑based intravenous infusion by trained healthcare professionals; dosing, infusion rates, and monitoring are individualized per the prescribing information and clinical response.

FDA Approval:

2019 – Asceniv™ (immune globulin intravenous, human — 10% liquid) was licensed by the FDA for the treatment of primary humoral immunodeficiency disease (PIDD) in adults and adolescents 12–17 years.

For more information, please visit the Asceniv™ patient website. Speak with your healthcare provider to determine if Asceniv™ is the right treatment option for you.